Therapeutic prospects of cannabidiol for ...
Type de document :
Article dans une revue scientifique: Article de synthèse/Review paper
DOI :
PMID :
URL permanente :
Titre :
Therapeutic prospects of cannabidiol for alcohol use disorder and alcohol-related damages on the liver and the brain
Auteur(s) :
De Ternay, Julia [Auteur]
Centre Hospitalier le Vinatier [Bron]
Naassila, Mickael [Auteur]
Université de Picardie Jules Verne [UPJV]
Nourredine, Mikail [Auteur]
Centre Hospitalier le Vinatier [Bron]
Louvet, Alexandre [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Bailly, François [Auteur]
Service d'Hépatologie [Hôpital de la Croix-Rousse - HCL]
Sescousse, Guillaume [Auteur]
Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center [CRNL]
Maurage, Pierre [Auteur]
Institut de recherche en sciences psychologiques [IPSY]
Cottencin, Olivier [Auteur]
Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193
Carrieri, Patrizia Maria [Auteur]
Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale [SESSTIM - U912 INSERM - Aix Marseille Univ - IRD]
Rolland, Benjamin [Auteur]
Centre Hospitalier le Vinatier [Bron]
Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center [CRNL]
Centre Hospitalier le Vinatier [Bron]
Naassila, Mickael [Auteur]
Université de Picardie Jules Verne [UPJV]
Nourredine, Mikail [Auteur]
Centre Hospitalier le Vinatier [Bron]
Louvet, Alexandre [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Bailly, François [Auteur]
Service d'Hépatologie [Hôpital de la Croix-Rousse - HCL]
Sescousse, Guillaume [Auteur]
Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center [CRNL]
Maurage, Pierre [Auteur]
Institut de recherche en sciences psychologiques [IPSY]
Cottencin, Olivier [Auteur]
Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193
Carrieri, Patrizia Maria [Auteur]
Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale [SESSTIM - U912 INSERM - Aix Marseille Univ - IRD]
Rolland, Benjamin [Auteur]
Centre Hospitalier le Vinatier [Bron]
Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center [CRNL]
Titre de la revue :
Frontiers in pharmacology
Nom court de la revue :
Front. Pharmacol.
Numéro :
10
Date de publication :
2019-05-31
ISSN :
1663-9812
Mot(s)-clé(s) en anglais :
alcohol-related damage
liver fibrosis and cirrhosis
neuroprotection
alcohol use disorder
cannabidiol
addiction
liver fibrosis and cirrhosis
neuroprotection
alcohol use disorder
cannabidiol
addiction
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Background: Cannabidiol (CBD) is a natural component of cannabis that possesses a widespread and complex immunomodulatory, antioxidant, anxiolytic, and antiepileptic properties. Much experimental data suggest that CBD could ...
Lire la suite >Background: Cannabidiol (CBD) is a natural component of cannabis that possesses a widespread and complex immunomodulatory, antioxidant, anxiolytic, and antiepileptic properties. Much experimental data suggest that CBD could be used for various purposes in alcohol use disorder (AUD) and alcohol-related damage on the brain and the liver. Aim: To provide a rationale for using CBD to treat human subjects with AUD, based on the findings of experimental studies. Methods: Narrative review of studies pertaining to the assessment of CBD efficiency on drinking reduction, or on the improvement of any aspect of alcohol-related toxicity in AUD. Results: Experimental studies find that CBD reduces the overall level of alcohol drinking in animal models of AUD by reducing ethanol intake, motivation for ethanol, relapse, anxiety, and impulsivity. Moreover, CBD reduces alcohol-related steatosis and fibrosis in the liver by reducing lipid accumulation, stimulating autophagy, modulating inflammation, reducing oxidative stress, and by inducing death of activated hepatic stellate cells. Finally, CBD reduces alcohol-related brain damage, preventing neuronal loss by its antioxidant and immunomodulatory properties. Conclusions: CBD could directly reduce alcohol drinking in subjects with AUD. Any other applications warrant human trials in this population. By reducing alcohol-related steatosis processes in the liver, and alcohol-related brain damage, CBD could improve both hepatic and neurocognitive outcomes in subjects with AUD, regardless of the individual’s drinking trajectory. This might pave the way for testing new harm reduction approaches in AUD, in order to protect the organs of subjects with an ongoing AUD.Lire moins >
Lire la suite >Background: Cannabidiol (CBD) is a natural component of cannabis that possesses a widespread and complex immunomodulatory, antioxidant, anxiolytic, and antiepileptic properties. Much experimental data suggest that CBD could be used for various purposes in alcohol use disorder (AUD) and alcohol-related damage on the brain and the liver. Aim: To provide a rationale for using CBD to treat human subjects with AUD, based on the findings of experimental studies. Methods: Narrative review of studies pertaining to the assessment of CBD efficiency on drinking reduction, or on the improvement of any aspect of alcohol-related toxicity in AUD. Results: Experimental studies find that CBD reduces the overall level of alcohol drinking in animal models of AUD by reducing ethanol intake, motivation for ethanol, relapse, anxiety, and impulsivity. Moreover, CBD reduces alcohol-related steatosis and fibrosis in the liver by reducing lipid accumulation, stimulating autophagy, modulating inflammation, reducing oxidative stress, and by inducing death of activated hepatic stellate cells. Finally, CBD reduces alcohol-related brain damage, preventing neuronal loss by its antioxidant and immunomodulatory properties. Conclusions: CBD could directly reduce alcohol drinking in subjects with AUD. Any other applications warrant human trials in this population. By reducing alcohol-related steatosis processes in the liver, and alcohol-related brain damage, CBD could improve both hepatic and neurocognitive outcomes in subjects with AUD, regardless of the individual’s drinking trajectory. This might pave the way for testing new harm reduction approaches in AUD, in order to protect the organs of subjects with an ongoing AUD.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
CNRS
Inserm
Université de Lille
CNRS
Inserm
Université de Lille
Collections :
Équipe(s) de recherche :
Troubles cognitifs dégénératifs et vasculaires
Date de dépôt :
2019-11-27T13:36:08Z
2020-03-24T09:30:04Z
2023-06-05T11:59:59Z
2020-03-24T09:30:04Z
2023-06-05T11:59:59Z
Fichiers
- fphar-10-00627.pdf
- Version éditeur
- Accès libre
- Accéder au document